BACKGROUND: With adoption of Model for End-Stage Liver Disease, the number of simultaneous liver-kidney transplants (SLK) has greatly increased. A recent registry study questioned the equity of allocating kidney transplants (KTx) simultaneously with liver transplantation due to poor outcomes (Locke et al., Transplantation 2008; 85: 935). METHODS: To investigate outcome of KTx in SLK, all SLK (n=36) performed at our center from January 2000 to December 2007 were reviewed and KTx outcomes compared with those of kidney transplant alone (KTA) performed during that period (n=1283). We also reviewed whether pretransplant panel reactive antibody and donor-specific antibody affected KTx outcome in SLK. RESULTS: One- and 3-year KTx and patient survival were not different between KTA and SLK regardless of sensitization level. There were 348 (27%) KTx failures in KTA vs. 6 (17%) in SLK (NS). Overall freedom from acute cellular rejection (ACR) and antibody-mediated rejection (AMR) in SLK was 93 and 96% at 3 years, compared with 72 and 78% in KTA (P=0.0105 and P=0.0744, respectively). Sensitized KTx recipients had more ACR and AMR (32 and 38%) at 3 years compared with nonsensitized recipients (28 and 20%) (P=0.23 and 0.0001, respectively). No differences in ACR and AMR were observed when SLK was divided and level of sensitization compared (P=0.17 and 0.65, respectively). CONCLUSION: SLK is a life-saving procedure with excellent patient and graft survival. AMR incidence in the KTx appears reduced in SLK compared with KTA regardless of level of preoperative panel reactive antibody. A high level of donor-specific antibody should not preclude simultaneous transplantation when clinically indicated.
BACKGROUND: With adoption of Model for End-Stage Liver Disease, the number of simultaneous liver-kidney transplants (SLK) has greatly increased. A recent registry study questioned the equity of allocating kidney transplants (KTx) simultaneously with liver transplantation due to poor outcomes (Locke et al., Transplantation 2008; 85: 935). METHODS: To investigate outcome of KTx in SLK, all SLK (n=36) performed at our center from January 2000 to December 2007 were reviewed and KTx outcomes compared with those of kidney transplant alone (KTA) performed during that period (n=1283). We also reviewed whether pretransplant panel reactive antibody and donor-specific antibody affected KTx outcome in SLK. RESULTS: One- and 3-year KTx and patient survival were not different between KTA and SLK regardless of sensitization level. There were 348 (27%) KTx failures in KTA vs. 6 (17%) in SLK (NS). Overall freedom from acute cellular rejection (ACR) and antibody-mediated rejection (AMR) in SLK was 93 and 96% at 3 years, compared with 72 and 78% in KTA (P=0.0105 and P=0.0744, respectively). Sensitized KTx recipients had more ACR and AMR (32 and 38%) at 3 years compared with nonsensitized recipients (28 and 20%) (P=0.23 and 0.0001, respectively). No differences in ACR and AMR were observed when SLK was divided and level of sensitization compared (P=0.17 and 0.65, respectively). CONCLUSION: SLK is a life-saving procedure with excellent patient and graft survival. AMR incidence in the KTx appears reduced in SLK compared with KTA regardless of level of preoperative panel reactive antibody. A high level of donor-specific antibody should not preclude simultaneous transplantation when clinically indicated.
Authors: Richard Ruiz; Hiroko Kunitake; Alan H Wilkinson; Gabriel M Danovitch; Douglas G Farmer; Rafik M Ghobrial; Hasan Yersiz; Jonathan R Hiatt; Ronald W Busuttil Journal: Arch Surg Date: 2006-08
Authors: Bekir Tanriover; Alejandro Mejia; Jeffrey Weinstein; Steven V Foster; Reem Ghalib; Abdullah Mubarak; Stephen S Cheng Journal: Transplantation Date: 2008-12-15 Impact factor: 4.939
Authors: R Bertelli; B Nardo; G Cavallari; G Ercolani; A Lauro; F Neri; M Tsivian; G L Grazi; P M Mikus; E Pilato; E Mikus; G Arpesella; A D Pinna; S Stefoni; G Fuga; A Faenza Journal: Transplant Proc Date: 2008 Jul-Aug Impact factor: 1.066
Authors: B E Lonze; D S Warren; Z A Stewart; N N Dagher; A L Singer; A S Shah; R A Montgomery; D L Segev Journal: Am J Transplant Date: 2009-03 Impact factor: 8.086
Authors: Jayme E Locke; Daniel S Warren; Andrew L Singer; Dorry L Segev; Christopher E Simpkins; Warren R Maley; Robert A Montgomery; Gabriel Danovitch; Andrew M Cameron Journal: Transplantation Date: 2008-04-15 Impact factor: 4.939
Authors: Richard Ruiz; Yousri M Barri; Linda W Jennings; Srinath Chinnakotla; Robert M Goldstein; Marlon F Levy; Greg J McKenna; Henry B Randall; Edmund Q Sanchez; Goran B Klintmalm Journal: Liver Transpl Date: 2007-06 Impact factor: 5.799
Authors: John C LaMattina; Joshua D Mezrich; Luis A Fernandez; Anthony M D'Alessandro; Janet M Bellingham; Alexandru I Musat; David P Foley Journal: Liver Transpl Date: 2011-05 Impact factor: 5.799
Authors: Islam M Korayem; Vatche G Agopian; Keri E Lunsford; Hans A Gritsch; Jeffrey L Veale; Gerald S Lipshutz; Hasan Yersiz; Coney L Serrone; Fady M Kaldas; Douglas G Farmer; Suphamai Bunnapradist; Gabriel M Danovitch; Ronald W Busuttil; Ali Zarrinpar Journal: Clin Transplant Date: 2019-05-07 Impact factor: 2.863
Authors: J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm Journal: Am J Transplant Date: 2014-03-01 Impact factor: 8.086
Authors: T J Borges; J T O'Malley; L Wo; N Murakami; B Smith; J Azzi; S Tripathi; J D Lane; E M Bueno; R A Clark; S G Tullius; A Chandraker; C G Lian; G F Murphy; T B Strom; B Pomahac; N Najafian; L V Riella Journal: Am J Transplant Date: 2016-04-07 Impact factor: 8.086
Authors: Flavio Paterno; Alin Girnita; Paul Brailey; David Witte; Jiang Wang; Madison C Cuffy; Tayyab Diwan; Simon Tremblay; Jane Y Revollo; Rita R Alloway; Michael R Schoech; Nadim Anwar; Shimul A Shah; Steve E Woodle Journal: Transplant Direct Date: 2016-11-23
Authors: Juan C Scornik; Jonathan S Bromberg; Douglas J Norman; Mayank Bhanderi; Matthew Gitlin; Jeffrey Petersen Journal: BMC Nephrol Date: 2013-10-10 Impact factor: 2.388